Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
WuXi XDC Cayman, Inc. ( (HK:2268) ) has shared an announcement.
WuXi XDC Cayman Inc. and BioDlink International Company Limited jointly announced the dispatch of a composite offer and response document for voluntary conditional cash offers for all issued shares of WuXi XDC not already owned by the offeror and its concert parties, as well as for the cancellation of all outstanding share options. The document, sent on 12 February 2026 and also available on the company and exchange websites, outlines offer details, an indicative timetable with a first closing date of 13 March 2026, and independent financial advice to shareholders and option holders, marking a key step in the potential change in ownership structure and governance oversight for the company.
The most recent analyst rating on (HK:2268) stock is a Hold with a HK$65.00 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.
More about WuXi XDC Cayman, Inc.
WuXi XDC Cayman Inc. operates in the biopharmaceutical sector, focusing on biologics and related drug conjugate development and manufacturing services. The company is part of a broader group that includes WuXi Biologics and serves global pharmaceutical and biotech clients seeking outsourced R&D and production capabilities.
Average Trading Volume: 4,459,236
Technical Sentiment Signal: Buy
Current Market Cap: HK$78.94B
Find detailed analytics on 2268 stock on TipRanks’ Stock Analysis page.